Gronigen, The Netherlands. AGILeBiotics BV has raised the next series of investment for the development of novel antibiotics against multidrug-resistant infections.

On 18th of July 2018, a deal was closed securing a joined investment from five regional investors, i.e. RUG Houdstermaatschappij BVStichting Ir. G.J. Smid Fonds BV, and Hanzepoort BV, Carduso Capital BV and Pharma Connect Capital BV. Whereas, the first three investment companies joined AGILeBiotics already in March 2017, Carduso Capital and Pharma Connect Capital become new shareholders with the recently acquired investment.

With this financial support AGILeBiotics is advancing novel antibiotic caniddates into pre-clinical development. Having now also Pharma Connect Capital and Carduso Capital on board the spin-off company aims to enter clinical studies in 2020.

About AGILeBiotics. AGILeBiotics BV was launched in March 2017 as a spin-off company of the University of Groningen (RUG). The start up has received an exclusive license from the RUG for the commercial use of a proprietary technology, which gives access to novel antibiotic candidates active against multidrug-resistant infections. With a pre-seed investment received from Hanzepoort BV, RUG Houdstermaatschappij BV and Stichting Ir. G.J. Smid Fonds BV in 2017, AGILeBiotics has already identified promising lead compounds showing superior activity against clinical important bacterial isolates of the ESKAPE panel. Compared to current treatment options AGILeBiotics’ drug candidates show improved activity against resistant pathogens and broader activity not only against Gram-negative but also Gram-positive bacteria.